Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 70/100

Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference

Key Takeaway: Ceribell, Inc. announced its participation in the 45th Annual TD Cowen Healthcare Conference, scheduled for March 3, 2025. The company's CEO and CFO will engage in a fireside chat at the event, enhancing its visibility in the medical technology sector. Ceribell focuses on the diagnosis and management of serious neurological conditions with its innovative EEG platform. A live webcast of the presentation will be accessible on the company's investor relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell is actively participating in a prominent healthcare conference.
  • The fireside chat offers visibility and potential interest from investors.
  • The company is at the forefront of innovative technology for neurological conditions.

Full Press Release Details

SUNNYVALE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming 45th Annual TD Cowen Health Care Conference. The fireside chat will take place on Monday, March 3, 2025, at 6:50 a.m. Pacific Standard Time / 9:50 a.m. Eastern Standard Time.
Event: 45th Annual TD Cowen Health Care Conference
Date: Monday, March 3, 2025
Time: 6:50 a.m. PST / 9:50 a.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Brian Johnston or Laine Morgan

Frequently Asked Questions

What is Ceribell's focus in medical technology?

Ceribell focuses on improving the diagnosis and management of serious neurological conditions.

When is the fireside chat at the TD Cowen Conference?

The fireside chat is scheduled for March 3, 2025, at 6:50 a.m. PST.

What does the Ceribell System do?

The Ceribell System is an EEG platform for rapid diagnosis and monitoring of neurological conditions.

Where can I watch the Ceribell presentation?

The presentation can be viewed on the Ceribell website's Investor Relations section.

Is the Ceribell System FDA cleared?

Yes, the Ceribell System is FDA 510(k) cleared for suspected seizure activity.

Last updated: Feb 18, 2025